Feb. 4 at 1:51 AM
$CLRB I don’t expect everything to go perfectly according to plan, but best-case CLRB catalyst roadmap for the rest of the year:
Feb: 131 partnership (or Mar)
Mar: 125 imaging data
131 pre-CMA meeting
Apr: 131 final data readout(or Jun at EHA)
May: 131 P3 confirmatory study start
Jun: 125 initial response data
Jul: 131 CMA submission
225 first patient enrolled
Aug: 131 NDA submission
Sep: 225 imaging data
The story isn’t just about CLR-131. CLR-125 and CLR-225 may ultimately prove even more valuable.
As new data readouts emerge, CLRB’s PDC platform is being validated step by step. If progress continues, a
$300 stock (~
$2B market cap, on a fully diluted basis) by the end of next year isn’t an unrealistic outcome — assuming AA/CMA approvals.
Let’s see how it plays out.
